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Influence of the Estrus Cycle and Female Sex Hormones
on GHB Toxicokinetics

Abstract

By Hao Wei
University of the Pacific
2018

Gamma-Hydroxybutyrate (GHB) is an endogenous short-chain fatty acid formed from
Gamma-aminobutyric acid (GABA). Clinically, GHB is marketed in the United States as Xyrem
to treat narcolepsy with cataplexy and in Europe for the treatment of alcohol withdrawal and
narcolepsy. However, the illicit use and abuse of GHB occurs due to its sedative/hypnotic and
euphoric effects. Monocarboxylate transporters (MCTs and SMCTs) are integral membrane
proteins that control the bidirectional transport of endogenous substrates including lactate,
acetate and pyruvate. They have also been found to transport and mediate the clearance and
distribution of GHB. MCTs demonstrate a wide tissue distribution, including brain, kidney, liver,
and intestine, all of which play an important role in determining the disposition of GHB.
Sex differences in drug elimination pathways contribute to the wide range of interindividual variability observed between sexes with respect to drug disposition and effect. Sex
differences in MCT expression have been observed in the brain, muscle, liver and kidney with
variations potentially driven by sex hormones; however, there is an absence of information on
how these expression differences translate into sex differences in GHB toxicokinetics. The
objective of this study was to evaluate sex differences and the influence of the estrus cycle on
GHB toxicokinetics after IV administration. Our hypothesis is that renal clearance and
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toxicokinetics will vary over the estrus cycle. Estrus cycle stage in female rats was determined
by vaginal lavage prior to GHB administration. Ovariectomized (OVX) females were included in
the study to evaluate GHB toxicokinetics in the absence of female sex hormones. Our results
demonstrated that sex and the estrus cycle influence GHB toxicokinetics. Total and renal
clearance varies over the estrus cycle with the highest renal clearance observed in proestrus
females. In contrast, males and OVX females demonstrated significantly lower renal clearance.
These results suggest that GHB toxicity and risk of overdose varies over the estrus cycle due to
expression changes in renal MCTs and SMCTs. Future studies will evaluate higher GHB doses
to determine the role of sex hormones in GHB overdose and fatality. In addition, hormone
replacement studies will be conducted to confirm the role of individual sex hormones on GHB
toxicokinetics.
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Chapter 1: Introduction
1.1 GHB
γ-hydroxybutyrate (GHB), also known as γ-hydroxybutyric acid, 4-hydroxybutyric acid,
4-hydroxybutanoic acid, is an endogenous four carbon chain fatty acid (X. Wang, Q. Wang, &
M. E. Morris, 2008). GHB is produced from γ-aminobutyric acid (GABA), which acts as a
neurotransmitter (Felmlee, Wang, et al., 2010). GHB is a neuromodulator in the central nervous
system , and interacts with the GHB and GABAB receptors (Schep, Knudsen, Slaughter, Vale, &
Megarbane, 2012). GHB is used clinically as Xyrem (sodium oxybate; Jazz Pharmaceuticals) to
treat narcolepsy with cataplexy in America (Felmlee, Roiko, Morse, & Morris, 2010), and to
treat alcohol withdrawal, heroin dependence, sleep disorders and narcolepsy in Europe (BoscoloBerto et al., 2012; Felmlee, Wang, et al., 2010). GHB, is most famous for its illicit use and abuse
in night clubs and raves and drug-facilitated sexual assault because of its sedative/hypnotic and
euphoric effects (X. Wang et al., 2008). GHB is colorless, odorless and tasteless, and has high
solubility, therefore it is easy to unknowingly administer a high dose. The dose-response curve
for GHB is very steep; minor increases in dose can lead to significant adverse events.
Toxicological effects of GHB include dizziness, respiratory depression, vomiting, and
unconsciousness, as well as coma and death (Felmlee, Roiko, et al., 2010).
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A

B

Figure 1: Chemical structure of (A) GHB and (B) GABA.

In Europe, the Drug Emergencies Network found that the top 5 drugs involved with
emergency department visits from September 2013 to September 2014 were heroin (1345 visits),
cocaine (954 visits), cannabis (904 visits), GHB (711 visits), and amphetamines (593 visits)
(White, 2017). Similarly, in Norway, there were 2923 episodes of acute poisoning from 2011 to
2012 in an emergency clinic and GHB accounted for 5% of the total (White, 2017). In the USA,
more than 7100 GHB overdose cases and 65 GHB related deaths were reported from 1990 to
2000 (Shannon & Quang, 2000). Although GHB has been strictly controlled as a schedule I drug
since 2000 in America (Felmlee, Wang, et al., 2010), it is still readily obtained and is also
formed in vivo from either 1,4-butanediol (BD) or γ-butyrolactone (GBL), which can be
obtained legally as industrial material (Fung et al., 2008).
The range of GHB doses typically seen in humans in abuse and overdose cases ranges
between 18 and 250 grams (Y. G. Wang, Swick, Carter, Thorpy, & Benowitz, 2009).
Therapeutic doses of sodium oxybate for narcolepsy range from 4.5 to 9 grams per night
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(Kantrowitz, Citrome, & Javitt, 2009). Case reports and case series regarding the features of
GHB poisoning provide a relatively consistent result for GHB toxicity in humans. When the
GHB dose is below 10 mg/kg, there will be mild clinical effects, such as short-term anterograde
amnesia, hypotonia, and euphoria (Schep et al., 2012). Drowsiness, sleep, and myoclonus can
occur following a dose of 20 - 30 mg/kg (Schep et al., 2012), whereas doses of 50 mg/kg and
higher can lead to coma (Schep et al., 2012). Doses over 50 mg/kg can result in the onset of
coma, bradycardia, and/or respiratory depression (Schep et al., 2012). Thus, patients may present
with symptoms ranging from sudden drowsiness to unresponsive and profound coma, determined
by the dose ingested. In rats, a dose of 200 mg/kg induces sleep and respiratory depression with
lethality observed at 1750 mg/kg (Felmlee, Roiko, et al., 2010; Morse, Vijay, & Morris, 2012).
Currently, there are no clinically available therapies to treat GHB overdose, and care focuses on
symptom treatment until the drug is cleared from the body.
1.2 GHB Toxicokinetics
GHB toxicokinetics are nonlinear both in rats and humans with capacity-limited
metabolism, renal clearance and oral absorption (Abanades et al., 2006; Felmlee, Wang, et al.,
2010; Ferrara et al., 1992; Lettieri & Fung, 1979; Palatini et al., 1993; X. Wang et al., 2008). In
humans, at a dose range of 40 – 72 mg/kg, GHB elimination is non-linear with clearance
parameters dependent on the dose administered (Abanades et al., 2006; Palatini et al., 1993). As
Figure 2A illustrates, GHB has a non-linear concentration versus time profile in rats following
intravenous administration of 200 to 1000 mg/kg resulting from saturable metabolism and renal
clearance (Felmlee, Wang, et al., 2010; Lettieri & Fung, 1979). In rats, GHB metabolic clearance
was saturated at all doses evaluated with a predicted in vivo Km for metabolism of 0.054 mg/ml
(Felmlee, Wang, et al., 2010). As GHB dose is increased, the renal clearance of GHB increases
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(Figure 2B). These dose-dependent increases in renal clearance suggest active, transportermediated, renal reabsorption of GHB (Felmlee, Wang, et al., 2010; Morris, Hu, & Wang, 2005).
GHB given by the oral route is rapidly absorbed. In rats, the plasma concentrations of
GHB plateau for a long time after oral administration due to saturation of intestinal absorption
and continuous absorption along the length of the intestine and colon (Morse & Morris, 2013a,
2013b; Vijay, Morse, & Morris, 2015). Due to saturation of intestinal transport, bioavailability of
GHB is nonlinear with decreased bioavailability with increasing dose (Lettieri & Fung, 1979).
GHB metabolism and renal clearance are also saturated at the doses given in oral administration
studies (Morse & Morris, 2013a, 2013b; Vijay et al., 2015). GHB is widely distributed in the
body with measureable concentrations in the mammalian brain, liver, kidney, intestine and other
peripheral tissues, and demonstrates tissue-specific nonlinear distribution consistent with the
involvement of monocarboxylate transporters (Felmlee, Morse, Follman, & Morris, 2017).
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Figure 2: Dose-dependent GHB plasma concentration versus time profiles and renal
clearance after IV administration in rats [data from (Felmlee, Wang, Cui, Roiko, & Morris,
2010)]. Pa <0.05 compared to 200mg/kg; Pb <0.05 compared to 400mg/kg.
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1.3 Monocarboxylate Transporters
Monocarboxylate transporters belong to the SLC16A family of proton-coupled
monocarboxylate transporters (MCTs) and the SLC5A family of sodium-coupled
monocarboxylate transporters (SMCTs). The SLC16A family was first identified in the midnineties, as transporters of endogenous monocarboxylic acids (Morris & Felmlee, 2008). Based
on sequence homology, fourteen MCT-related genes of this family have been identified in
mammals (Morris & Felmlee, 2008). Of the 14 identified members, eight MCTs have been
functionally characterized: MCTs 1-4, MCT6, MCT8, MCT10, and MCT12 (Morris & Felmlee,
2008; Schwartz & Stevenson, 2007). MCTs have a wide tissue distribution including the liver,
stomach, colon, ileum, and kidney, likely due to their role in the transport of endogenous
monocarboxylates which function as cellular energy sources (Morris & Felmlee, 2008). MCTs
may be located on basolateral or apical membrane depending on the specific cell type (Morris &
Felmlee, 2008).
MCTs 1 - 4 are the most abundant and widely studied, and are the only members of the
family that demonstrate proton-coupled transport of monocarboxylates. MCT1 - 4 transport
endogenous and exogenous compounds including lactate, pyruvate, butyrate, acetate, valproic
acid, GHB, and pravastatin (Morris & Felmlee, 2008). Other characterized MCTs have been
demonstrated to transport a wide variety of endogenous and/or exogenous compounds: MCT6 is
a transporter of bumetanide, nateglinide, and probenecid; MCT8 is transporter of thyroid
hormones; MCT10 is transporter of aromatic amino acids; and MCT12 is transporter of
creatinine (Jones & Morris, 2016).
MCT1 (SLC16A1) was the first member of MCT family to be identified (Jackson, Price,
& Halestrap, 1995). The proposed topological structure of MCT1 has 12 transmembrane helices
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with intracellular C- and N-termini (Halestrap, 2013; Halestrap & Price, 1999). MCT1 in a
closed conformation has cytosolic substrate binding site, and in the open conformation has an
extracellular substrate binding site (Halestrap, 2013). DIDS, and MCT inhibitor, is proposed to
interact with four extracellular lysines residues of MCT1 (K38, K45, K282 and K413)
(Halestrap, 2013). This topology is predicted to be shared by all members of the SLC16 family;
however, to-date no crystal structures are available for any SLC16Amembers or SLC5A8 or
SLC5A12.
Within the SLC5A family, two sodium-couple monocarboxylate transporters have been
identified: SLC5A8 (SMCT1) and SLC5A12 (SMCT2). SMCT1 was first identified in 2003 by
Li et al. (Li et al., 2003) , and SMCT2 was identified in 2005 by Srinivas et al. (Srinivas et al.,
2005). SMCT1 and 2 are predominantly expressed in intestine and kidney, with no expression
demonstrated in other tissues (20). SMCTs are typically expressed on the apical membrane of the
cell (Iwanaga & Kishimoto, 2015). In contrast to MCTs, which function as H+-coupled
electroneutral transporters, SMCTs function as Na+-coupled electrogenic transporters with
SMCT1 having a 2:1 transport ratio (Na+:substrate) (Cui & Morris, 2009). Although there is no
structural similarity between MCT1 and SMCT (Ganapathy et al., 2008), and the transport
mechanism is different as well between the two transporters, both of transporters have similar
substrate specificity (Ganapathy et al., 2008). Endogenous substrates of SMCTs include lactate,
acetate, propionate, and butyrate (Ganapathy et al., 2008; Iwanaga & Kishimoto, 2015). SMCTs
also functions as drug transporters to regulate the intestinal absorption and renal clearance of
various monocarboxylate drugs including GHB, salicylates, benzoate, and non-steroidal antiinflammatory drugs (Ganapathy et al., 2008; Iwanaga & Kishimoto, 2015).
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1.4 Monocarboxylate Transporters and GHB Toxicokinetics
GHB is a substrate for MCTs and SMCTs. It has been demonstrated that MCT inhibition
is a potential treatment strategy for GHB overdose by inhibiting its active renal reabsorption
mediated by MCTs and SMCTs and subsequently increasing GHB renal clearance (Morris et al.,
2005; Morris et al., 2011; Vijay et al., 2015). Administration of MCT inhibitors such as L-lactate
results in an increase in GHB renal and total clearance in rats (Roiko, Vijay, Felmlee, & Morris,
2013a; Q. Wang, X. Wang, & M. E. Morris, 2008). Similarly, after luteolin treatment, the renal
and total clearances of GHB are significantly increased because of inhibition of the MCT1mediated renal reabsorption (Q. Wang & Morris, 2007). As well, some immunosuppressive
compounds such as AR-C117977 and AR-C122982 (Pahlman et al., 2013) have been identified
as potent MCT inhibitors to increased GHB renal and total clearance (Vijay et al., 2015).
The sedative/hypnotic effects of GHB and respiratory depression were seen during
overdose resulting from its effects in the brain (Morse et al., 2012; Roiko et al., 2013a). In brain,
GHB can interact with GHB – specific receptor and GABAB receptor (Morse et al., 2012; Roiko
et al., 2013a) .It has been demonstrated GHB exhibits uptake into the frontal cortex which is
mediated by MCT and was saturated at high GHB concentrations (Roiko, Felmlee, & Morris,
2012). Administration of MCT inhibitor L-lactate decreased brain extracellular fluid
concentration of GHB and decreased sedative/hypnotic effects (Roiko et al., 2013a).
Variations in MCT/SMCT expression in the kidney can alter renal reabsorption and
renal clearance of GHB (Felmlee, Dave, & Morris, 2013; Felmlee, Wang, et al., 2010). Higher
MCT/SMCT expression will lead to a greater amount of GHB being reabsorbed into systemic
circulation, therefore the total amount of GHB excreted in the urine and GHB renal clearance are
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lower (Felmlee et al., 2013). In contrast, lower MCT/SMCT expression will lead to the higher
renal clearance and an increase in total GHB elimination.
1.5 Sex Differences in MCT Expression
The estrus cycle is the reproductive cycle in mammalian females and consists of varied
exposure to female sex hormones. Previous studies show that the estrus cycle in female rats can
be divided into four stages (Figure 3): proestrus, estrus, metestrus, diestrus (Cora et al., 2015). In
different stages, plasma sex hormone concentrations are different and may contribute to
differences in transporter expression (Haim, Shakhar, Rossene, Taylor, & Ben-Eliyahu, 2003).
The highest concentrations of estrogen and progesterone are observed in the proestrus stage
(Figure 3 from (Lebron-Milad & Milad, 2012)).
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Figure 3: Hormone exposure over the estrus cycle [from (Lebron-Milad & Milad, 2012)].

There is limited literature data evaluating sex differences and the influence of sex hormones
on MCT expression. Sex differences in MCT expression have been observed in the muscle,
brain, and Sertoli cells with variation driven by sex hormones (Enoki, Yoshida, Lally, Hatta, &
Bonen, 2006; Manente et al., 2015; Rato et al., 2012). Administration of testosterone increased
MCT1 and MCT4 protein expression in rat skeletal muscle; however, expression was not altered
in the heart suggesting tissue specific hormonal regulation mechanisms (Enoki et al., 2006).
Further, it has been demonstrated that oestrogen-related receptor alpha (ERRα) expression can
modulate the expression of MCT1 in mice (Aveseh, Nikooie, & Aminaie, 2015), while the
induction of estrogen receptor β (ERβ) expression result in the expression of MCT4 in cell level
in mesothelioma cells of mice (Manente et al., 2015). Ovariectomy (OVX) induced a decrease of
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MCT2 expression in brain of mice (Manente et al., 2015) suggesting that female sex hormones
are involved in MCT regulation.
There is a lack of data evaluating the influence of sex and sex hormones on MCT/SMCT
expression in drug distribution tissues. Our laboratory has previously demonstrated that MCT1
and MCT4 hepatic expression varies between males and females, over the estrus cycle and in the
absence of female sex hormones (Figure 4 from (Cao et al., 2017)). In the liver of rats, MCT1
membrane expression shows a significant difference in cycling females as compared to males
and OVX females. The proestrus MCT1 membrane expression is the lowest and was
significantly lower than OVX females (Cao et al., 2017). Females in the other estrus stages had
higher MCT1 expression than proestrus females, but still lower compared to males and OVX
females (Cao et al., 2017). Membrane expression of MCT4 was also significantly different
between sexes with all females having lower expression than males with proestrus females
having significantly lower expression than males (Cao et al., 2017). Our results suggest that
expression of individual MCTs are differentially regulated by sex hormones. Preliminary work in
our laboratory has also demonstrated that both male and female sex hormones influence
intestinal and renal expression of MCTs.
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Figure 4: MCT1 and MCT4 membrane expression in the liver over the estrus cycle and in
the absence of female sex hormones (from (Cao et al., 2017)). Data are presented as mean
± SD (N = 3-5). P# <0.05 compared to OVX group; P* <0.05 compared to male group.

1.6 Sex Differences in Expression of Other Drug Transporters
A number of drug transporters have been shown to be influenced by sex with
differences in protein or mRNA expression. The oral administration of PEG 400 decreased the
P-glycoprotein expression in the jejunum, ileum and colon of males, but not in the corresponding
segments in females (Mai, Dou, Murdan, & Basit, 2018). In addition, estriol and ethynyl
estradiol exposure resulted in concentration-dependent increases in mRNA expression of
ABCB1, which encodes P-glycoprotein (Peng, Zhang, Zhang, & Wei, 2015). As well, sex
differences in rat renal expression of OAT1 and OAT3 (both are p-aminohippurate transporter in
kidney) have been observed after puberty, and are determined by androgens and estrogens
(Ljubojevic et al., 2004). In another study, treatment of testosterone, both in male and female
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rats, significantly increased both of mRNA and protein expression of OCT2 (organic cation
transporter) in the kidney, while estradiol treatment moderately decreased the expression rOCT2
(Urakami, Okuda, Saito, & Inui, 2000).
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Chapter 2: Thesis Objectives
GHB is widely used at nightclubs and raves, and is commonly used in drug-facilitated
sexual assault. Despite the potential for illicit use and abuse in women, there is a lack of
toxicokinetic data in female rats and humans. Our laboratory has previously identified sex
differences in MCT expression in the liver and kidney suggesting that sex differences may be
observed in GHB toxicokinetics. The LD50 of GHB is 1750mg/kg; a dose of 600mg/kg was
selected as a mid-range dose, to avoid fatality as the variability between sexes is unknown.
The objective of this study is to evaluate sex differences and the influence of estrus cycle
on GHB toxicokinetics and renal clearance after IV administration. Our hypothesis is that renal
clearance and toxicokinetics will vary over the estrus cycle. We will evaluate GHB
toxicokinetics following 600 mg/kg intravenous GHB over the estrus cycle in females, in the
absence of female sex hormones and in male rats.

24

Chapter 3: Methods
3.1 Chemicals and Reagents
GHB (sodium salt) was obtained from the NIDA Drug Supply Program. Formic acid was
purchased from Fisher Scientific (Fair Lawn, NJ). Deuterated GHB (GHB-d6) was obtained from
Sigma-Aldrich (St. Louis, MO). Ketamine, xylazine, and heparin were purchased from Patterson
Veterinary (Saint Paul, MN). High-performance liquid chromatography (HPLC)-grade
acetonitrile, methanol, and acetic acid were purchased from Fisher Scientific (Fair Lawn, NJ).
3.2 Animals
Male and female Sprague Dawley (SD) rats and ovariectomized females were obtained
from Charles River at 8 weeks of age. They were housed in a temperature-controlled room with a
12-hour day/night lighting cycle and were housed individually after surgical procedures. All rats
were fed standard rat chow and water ad libitum.
3.3 Estrus Cycle Staging
The estrus cycle typically lasts for four to five days in rats and is a repetitive, but
dynamic process (Cora et al., 2015). During the estrus cycle, there are different cell types that
appear and disappear throughout the process. All cell type descriptions are based on cytology
slides prepared from vaginal smears which are stained by crystal violet (Manente et al., 2015).
There are three different cell types in vaginal smears (Figure 5 from (Cao et al., 2017)).
Nucleated epithelial cells (arrow 1) are round to oval cells with a nucleus which can be
visualized clearly (Figure 5A ,5C and 5D). In some reviews, nucleated epithelial cells are
divided into large and small cells (Cora et al., 2015), but this is not necessary to assign estrus
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cycle stage. Anucleated epithelial cells (arrow 2) are irregular polygonal cells without a nucleus.
The pale area in the center of the cell is the position where the nucleus existed (Figure 5B, 5C
and 5D). Neutrophils (arrow 3), also called leukocytes, are round nucleated cells and are the
amallest cells in vaginal cytology. During the smear collection, these cells are easily broken
making it difficult to visual the nuclei. The presence of neutrophils is illustrated in Figure 5C and
5D.
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A

B

C

D

Figure 5: Different cell types in vaginal smears at 20 times magnification (from (Cao,
Ng, & Felmlee, 2017)).
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Estrus stage is determined according to the absence, presence, and proportion of the
different cell types and cell density. Generally, the cycle can be divided into four stages:
proestrus, estrus, metestrus, and diestrus. Proestrus is a short stage, averaging 14 hours in rats
(Cora et al., 2015), and is characterized by the presence of predominately small, round, nucleated
epithelial with moderate to low cellularity. Estrus lasts between 24 and 48 hours (Cora et al.,
2015). The predominant feature of this stage is the presence of anucleated keratinized epithelial
cells with high cell density. Numerous bacteria may be observed adhered to the cells or free in
the background. Metestrus is a short stage of 6 - 8 hours in rats (Cora et al., 2015) and the main
feature of this stage is a combination of nucleated epithelial cells, anucleated keratinized
epithelial cells and neutrophils. The number of neutrophils is very high, 10 times more than the
number of epithelial cells. In the late phase of metestrus, the number of different cells all
decrease leading to a decrease in cell density. Diestrus is the longest stage of the estrus cycle and
the duration ranges from 48 to 72 hours in rats (Cora et al., 2015). The cellularity is moderate to
low with a combination of neutrophils, small and large nucleated epithelial cells, and low
numbers of anucleated keratinized cells. Table 1 describes the classification of estrus cycle
stages based on cell types and relative number of these cell types in vaginal smears. According to
the shape, size, with or without nuclei, cell can be divided into 3 types neutrophils, nucleated
epithelial cells, and anucleated keratinized epithelial cells. After imaging, based on the number
of different types of cells and relative cell density, estrus cycle stage of each rat was determined
daily.
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Table 1: Basic classification of the stages of estrous cycle based on cell types and relative
numbers of these cell types in vaginal smears (modified from reference (Cora, Kooistra, &
Travlos, 2015)).

Note: 0 = none; + = few; ++ = moderate; +++ = high.

Collection of the vaginal cytology samples was done by vaginal lavage. To elucidate the
estrus cycle length and to ensure the accuracy of each stage on the day of the pharmacokinetic
study, vaginal smears were collected over at least 2 consecutive cycles between 9 am – 11 am
every day. Rats were under anesthesia (isoflurane: 3 – 4 % induction and 2% maintenance) for
the duration of the vaginal lavage.
3.3.1 Vaginal lavage procedure. 1) Draw up approximately 100 μl of sterile ddH2O
using a disposable pipet tip; 2) Placed the rat rear end towards you; 3) Grasp the tail and lift the
rear end, and then insert the end of the ddH2O-filled tip into vaginal canal orifice at a depth of
approximately 5–10 mm in rats (Cora et al., 2015) (this step was done very gently to avoid
stimulation, which may lead to pseudopregnancy in rats (Cora et al., 2015)); 4) The ddH2O was
flushed into the vagina and back out 2 to 3 times.
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After lavage, the sample was placed on a microscope slide and was dried at room
temperature. 0.1% crystal violet was used to stain vaginal cytology samples. A three-step
staining procedure was used: 1) Placed the dry slides into 0.1% crystal violet and stain for 1 min;
2) the slide was removed and placed into sterile ddH2O to wash it; 3) Step 2 was repeated and the
slides were airdried. Cytology samples were identified using a 20 times objective of BZ-X710
microscope (Keyence, Itasca, IL). The cytology sample figures were captured by the Capture
Still Images mode of BZ-X Viewer.
3.4 Surgery
A jugular vein cannula was implanted in all animals for drug administration and blood
sampling. All steps were under sterilized conditions (sterilized towel and tools). Rats were
administered ketamine/xylazine (90 mg/kg ketamine +10 mg/kg xylazine) to maintain the
anesthetic plane during surgery. During surgical procedures, the anesthetic state was maintained
by supplemental doses of anesthetic if needed. The rats were anesthetized, shaved and the skin
swabbed sequentially with soap, alcohol and betadine. Two incisions were made, one on the
back (between the rat's shoulder blades) for exteriorizing the jugular catheter and one on the
upper right quadrant of the rat's chest for jugular vein catheterization. The subcutaneous tissue
and muscle bed were gently teased apart to expose the vein. A sterile saline-filled catheter
(MRE-040 tubing, OD 0.040 inch, ID 0.025 inch; Braintree Scientific) for systemic drug dosing
and systemic blood sampling was implanted into the jugular vein (approximately 3 mm),
anchored with silk suture (4-0), and tunneled subcutaneously to the shoulder and exteriorized
between the shoulder blades. The skin incisions were sealed with surgical staples and triple
antibiotic (Patterson Veterinary) was applied to the wounds. Buprenorphine (0.05 mg/kg sc) and
saline (2 ml sc) were given immediately following the surgery for pain management and fluid
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replacement. The rats were monitored (respiratory rate, pain reflex and the color of toe, eye and
mucous membrane) every 15 minutes until they recovered and were moving freely. Cannulas
were flushed with heparinized saline (40 IU/mL daily to ensure cannula patency for the
toxicokinetic studies). Surgery was performed at least two days before the toxicokinetic studies.
3.5 Toxicokinetic Study Design
GHB was dissolved in doubled-distilled water (300 mg/ml) and filtered with 0.2 µm
filters to ensure sterility. GHB (600 mg/kg) was administered by intravenous bolus injection via
the jugular vein cannula to male, different estrus cycle stage females, and ovariectomized female
Sprague-Dawley rats (n = 4 - 5 per group). Each estrus stage evaluated represents an independent
group of animals. Ovariectomized females were included to evaluate toxicokinetics in the
absence of sex hormones. All rats were dosed in metabolic cages with ad libitum access to water
to allow for the simultaneous collection of blood and urine sample for up to 6 hours. The time of
sedative/hypnotic effect onset (LRR) and offset (RRR) was recorded for all the animals. The
LRR and RRR is the time when the animal lost or regained the ability to right itself when placed
on their back. The animals were placed on their back immediately after dosing and the
sedative/hypnotic effect was checked every 30 s until LRR. Blood samples (200 µl) were taken
from the jugular vein cannula at different time points (10, 30, 60, 90, 120, 180, 210, 240 and 270
minutes) and transferred into heparinized 0.65 ml microcentrifuge tubes. Plasma samples were
separated by centrifugation at 5000 rpm for 15 minutes at 4℃ and stored at -20℃. Urine samples
were collected at 120, 240, 360 minutes, the total urine volume was determined and the sample
was transferred into 15 ml centrifuge tubes and stored at -20℃.
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3.6 Coordination of Studies
Animals were received, and acclimatized for at least two days before evaluation of the
estrus cycle. To elucidate the estrus cycle length and to ensure the accuracy of the stage on the
day of the TK/PD study, vaginal smears were collected over at least 2 consecutive cycles (about
8-10 days). Surgical implantation of the jugular cannula was done at least two days before TK
studies to allow for animal recovery. Vaginal smears and estrus stage determinations were
performed on the days of surgery, surgical recovery and the TK study day to make ensure the
accuracy of the estrus cycle stage. Vaginal smears were always collected in the morning as
described above. Animals were excluded from the study if the jugular cannula implantation was
not successful (or lost patency) or if the estrus cycle stage could not be definitively assigned (ie.
if there was the possibility of pseudopregnancy).
3.7 Sample Preparation
3.7.1 Plasma preparation. GHB plasma sample preparation followed a previously
published method (Felmlee, Roiko, et al., 2010). GHB standard stock solutions for plasma
samples were prepared in double-distilled water at the following concentrations: 10, 50, 100,
250, 1250, 2500, 5000 µg/ml. Quality control stock solutions were prepared separately at 100
and 5000 µg/ml for low QC and high QC, respectively. For standards and quality controls, 5 µl
of GHB-d6 (500 µg/ml), 5 µl of standard stock solution or QC stock solution was combined with
45 µl of blank plasma. For each unknown plasma sample, 5 µl of GHB-d6 (500 µg/ml) was
added to 50 µl plasma. Plasma samples obtained at 120 minutes or less after GHB administration
were diluted 10-fold with blank plasma. 800 µl of acetonitrile with 0.1% formic acid was added
to all samples and standards to precipitate plasma proteins followed by centrifugation at 10000
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rpm for 20 minutes. 750 µl of the supernatant was removed, transferred to a clean
microcentrifuge tube and evaporated by using CentriVap Concentrator (Labconco, Kansas City,
MO) under vacuum status. Dried samples were reconstituted in 250 µl of 95:5 ddH2O:
acetonitrile with 0.1% acetic acid.
3.7.2 Urine preparation. Urine sample preparation followed a previously published
method with minor modifications (Felmlee, Roiko, et al., 2010). GHB standard stock solutions
for urine samples were prepared in double-distilled water at the following concentrations: 10, 20,
100, 200, 400, 1000, 2000 µg/ml. Quality control stock solutions were prepared separately at 20,
200 and 1000 µg/ml (in double-distilled water) for QC-low, QC-mid and QC-high, respectively.
All urine samples and blank urine were diluted 100-fold (5 µl urine in 495 µl double-distilled
water). For standards and QCs, 25 µl of diluted blank urine, 5 µl of standard or QC stock
solution, 5 µl of GHB-d6 (500 µg/ml) and 465 µl ddH2O were combined. For unknown urine
samples, 25 µl diluted sample, 5 µl GHB-d6 (500 µg/ml) and 470 µl ddH2O. Samples were stored
at -20℃ until liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis.
3.8 LC/MS/MS Assay
GHB in plasma and urine was quantified using a validated LC/MS/MS assay described
previously with minor modifications (Felmlee, Roiko, et al., 2010). The LC/MS/MS system
included an Agilent 1100 series HPLC consisting of an online degasser, binary pump, and
autosampler (Agilent Technologies, Santa Clara, CA) connected to MDS Sciex API 3000 triple –
quadruple tandem mass spectrometer equipped with a turbo ion spray (Applied Biosystems,
Foster City, CA). 20 µl of sample was injected into an Xterra MS C18 column (250 × 2.1 mm
i.d., 5-µm particle size; Waters, Milford, MA). Mobile phase A was 0.1% formic acid in double-
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distilled water with 5% acetonitrile. Mobile phase B was 0.1% formic in acetonitrile with 5%
double-distilled water. A gradient elution with a flow rate of 200 µl/min was used to separate
compounds: 100 % to 90% A over 5 min, 90% to 10% A over 2.5 min, and 10% to 100% A over
4.5 min. The total running time is 12 minutes. The mass spectrometer was operated in positive
ionization mode with multiple reaction monitoring. Table 2 shows the detail of the mass
spectrometer parameters of GHB and GHB-d6.

Table 2: Mass spectrometer parameters for MRM of GHB

3.9 Data Analysis
Data are presented as mean ± standard deviation. Data was analyzed in GraphPad Prism
7.05 using a nonparametric one-way analysis of variance (ANOVA) with a Tukey’s post hoc test
to evaluate for differences between group. A P value less than 0.05 was considered statistically
significant.
Non-compartmental analysis of the plasma concentration time profiles was conducted in
Phoenix WinNonLin to obtain AUCinf and total clearance (CL). Cumulative urinary excretion of
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GHB was calculated by summing the amount excreted in urine for all three collection intervals.
Fraction of drug eliminated in the urine (fe) is the quotient of cumulative excretion divided by the
product of dosage and body weight (fe = Ae,inf/(Dose*BW)). Renal clearance (CLR) was
calculated as the total amount excreted in urine divided by the plasma AUC (CLR = Ae,inf/AUC).
Metabolic clearance (Clm) was calculated as the difference of total clearance and renal clearance
[CLm = CL – CLR]. The sleep time following GHB administration was determined as the
difference between RRR and LRR.
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Chapter 4: Results
4.1 GHB LC-MS/MS Assay
The retention time for GHB and GHB-d6 was 3.57 minutes. The standard curve in
plasma is from 1 to 500 µg/ml (Figure 6A) and in urine from 2 µg/ml to 400 µg/ml (Figure 6B),
based on regression analysis (r2 >0.99) of the peak area ratio (GHB/GHB-d6) versus GHB
concentration. Inter- and intra-day accuracy and precision based on quality control samples of
the analyte were 100 ± 10%.
4.2 Estrus Staging
After imaging, the estrus stages of cycling female rats were identified by different cell
types and cell density (shown in Figure 5). Figure 7 shows representative images of the four
stages from the current study. Proestrus was identified by large, round nucleated epithelial cells
(Figure 7A). Estrus was identified by large, anucleated keratinized epithelial cells (Figure 7B).
Metestrus was identified by a high density of epithelial cells and neutrophils (Figure 7C).
Diestrus was identified by a low density of epithelial cells and neutrophils (Figure 7D).
4.3 Toxicokinetic Analysis
Figure 8 shows the GHB concentration versus time profiles in plasma of individual
groups after 600 mg/kg IV administration. Figure 8A is an overlay of all groups with the
different color solid lines representing individual groups. It shows GHB has a non-linear
toxicokinetic profiles following IV administration in all rats, regardless of sex or estrus stage, as
a result of saturable metabolism and renal clearance. The Cmax (the plasma concentration of 10
min) of males, and proestrus and estrus females are lowest compared to the other groups, while
the Cmax of diestrus females is the highest, suggesting that there may be estrus cycle dependent
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differences in the initial distribution of GHB. The terminal phases have different slopes, which
suggests that elimination is different between groups. As we can see, the terminal phase curve of
proestrus was sharper than the other groups, whereas both the OVX and male were shallower
than the cycling female suggesting greater clearance in proestrus rats. In cycling females (Figure
8B), the slope of terminal phase varies by estrus cycle stage (proestrus > estrus > metestrus >
Diestrus).
Non-compartmental analysis of the plasma concentration time profiles was conducted in
Phoenix WinNonLin and the results are presented in Figure 9. Total clearance (Figure 9A) was
significantly influenced by sex and the estrus cycle (P 0.0466), with proestrus and estrus females
trending higher than other groups. The clearance of diestrus females is the lowest of all groups
with both of OVX and males having slightly higher clearance values as compared to diestrus
females. The total clearance results are consistent with the calculated AUC values (Figure 9B):
groups with higher clearance values had lower AUCs. While AUC values varied over the estrus
cycle, after statistical analysis, there was no significant difference with one-way ANOVA (P =
0.0750). Proestrus had the lowest AUC and the highest AUC was observed in diestrus consistent
with the calculated clearance values. The AUC of OVX and males were higher than all estrus
stages except diestrus.
Renal clearance and the fraction of drug eliminated in the urine (fe) are presented in
Figure 10 and were calculated from urinary excretion data (Figure 9). Renal clearance varied
significantly with sex and the estrus cycle (P = 0.0011); the highest renal clearance was observed
in proestrus females and renal clearance declined over the subsequent stages with significantly
lower renal clearance in diestrus females. Renal clearance was significantly lower in OVX and
male animals as compared to proestrus females. fe demonstrated a similar trend to renal clearance
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and varied with sex and the estrus cycle (P = 0.0279), with OVX females demonstrating a
significantly lower fe as compared to proestrus females. These results are consistent with the
observed sex and estrus cycle differences in AUC.
The calculated metabolic clearance is presented in Figure 11. There was no significant
difference over the estrus cycle, in OVX females or males (P = 0.8066). This suggests that there
are no sex or estrus cycle differences in metabolic clearance.
4.4 Pharmacodynamic Analysis
Sleep time trended lower in proestrus and estrus females consistent with the observed
differences in toxicokinetics; however, the sedative/hypnotic effect of GHB showed no
significance with sex or the estrus cycle (P = 0.5480) (Figure 12).
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Figure 6: Standard curve of (A) GHB in plasma (r = 0.9999) and (B) GHB in urine
2
(r = 1.0000).
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Figure 7: Representative vaginal smears of the four estrus stages. (A) proestrus, (B) estrus,
(C) metestrus, and (D) diestrus. Stages were determined as described in the methods section
and in Figure 5.
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Figure 8: GHB plasma concentrations following intravenous administration of 600 mg/kg to
males, OVX females and females at each estrus stage. Data presented as mean ± SD, N = 4 –
5.
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Figure 9: (A) Total clearance and (B) Area under the plasma concentration-time profile
(AUC) following administration of 600 mg/kg iv in males, OVX females and females at
each estrus stage. Parameters were calculated for each animal utilizing NCA analysis in
Phoenix WinNonLin. Data are presented as mean ± SD, N = 4 – 5.
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Figure 10: (A) Fraction of drug eliminated in urine (fe) and (B) renal clearance following
administration of 600 mg/kg iv in males, OVX females and females at each estrus stage.
Parameters were calculated for each animal based on cumulative urinary excretion of GHB
utilizing the equations described in the methods section. Data are presented as mean ± SD, N
#
= 4 – 5. *P < 0.05 compared to proestrus group. P < 0.05 compared to estrus group.
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Figure 11: GHB metabolic clearance (CLm) following administration of 600 mg/kg iv in
males, OVX females and females at each estrus stage. CLm was calculated as the difference
between total clearance and renal clearance (as described in the methods section). Data are
presented as mean ± SD, N = 4 – 5.
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Figure 12: Sedative/hynopic effect of GHB following administration of 600 mg/kg iv in
males, OVX females and females at each estrus stage. Sleep time represents the difference
between RRR and LRR. Data presented as mean ± SD, N = 4 – 5.
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Chapter 5: Discussion
GHB demonstrates non-linear toxicokinetics in rats following intravenous
administration resulting from saturable metabolism and renal clearance (Felmlee, Wang, et al.,
2010). Capacity-limited GHB renal clearance is due to saturation of active renal reabsorption via
monocarboxylate transporters (Felmlee, Wang, et al., 2010; Morris et al., 2005). Membrane
MCT/SMCT expression directly relates to the maximum capacity for the transporters to move
GHB across the plasma membrane. Alterations in renal MCT/SMCT expression may lead to
changes in GHB renal clearance and systemic drug concentrations. Previous studies have
reported that MCT expression is driven by sex hormones in liver, skeletal muscle and brain (Cao
et al., 2017; Enoki et al., 2006; Manente et al., 2015); however, there are no studies evaluating
sex differences and the impact of sex hormones on GHB toxicokinetics. The current study is the
first analysis of the influence of the estrus cycle and female sex hormones on GHB
toxicokinetics. We have demonstrated that renal clearance differs between sexes, over the estrus
cycle in females, and in the absence of female sex hormones. In contrast, metabolic clearance
shows no difference between sexes or over the estrus cycle.
GHB demonstrates nonlinear toxicokinetics due to capacity-limited metabolism (Palatini
et al., 1993) and renal reabsorption (Morris et al., 2005). Metabolic clearance is saturated and
renal clearance becomes a significant route of elimination in GHB overdose. The toxicokinetic
profiles in our study are consistent with previous studies reporting GHB toxicokinetics in male
rats (Felmlee, Roiko, et al., 2010; Felmlee, Wang, et al., 2010; Lettieri & Fung, 1979). The
concentrations which lead to death in humans (post-mortem blood levels: mean 660 mg/L)
(Corkery, Loi, Claridge, Goodair, & Schifano, 2018) are lower than those that cause death in
rats. However, the concentrations in current study are in the range of those seen in human
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overdose. The current study shows similar total clearance in males as compared to previous
literature, which indicated a GHB total clearance of 6.00 ml/min/kg and GHB renal clearance of
1.68 ml/min/kg following iv administration of 600 mg/kg (Morse et al., 2012). In addition for
sedative/hypnotic effect, we demonstrated a consistent sleep time under the same overall plasma
exposure (AUC) as seen in previous studies (Felmlee, Roiko, et al., 2010) with shorter sleep
times observed in animals with lower plasma AUC values. As reported, the co-administration of
lactate, which is the inhibitor of MCTs and SMCTs, can decrease the overall plasma exposure,
increase renal clearance, and decrease sleep time, which represents the sedative/hypnotic effect
(Roiko, Vijay, Felmlee, & Morris, 2013b) illustrating that modulation of MCT/SMCT-mediated
renal reabsorption impacts GHB renal clearance. The dose used in the current study is relatively
low fora toxicokinetic study of GHB; however, it was selected to avoid fatality (Dave, Follman,
& Morris, 2017; Felmlee, Roiko, et al., 2010; Morse & Morris, 2013b; Morse et al., 2012), as it
was unclear how large the differences over the estrus cycle would be. Future studies will
evaluate higher doses of GHB (up to 1500 mg/kg) to evaluate the impact of sex hormones and
the estrus cycle on risk of GHB-induced fatality.
MCT inhibition is a potential treatment strategy for GHB overdose by inhibiting its active
renal reabsorption mediated by MCTs and SMCTs (Morris et al., 2005). To further develop this
therapeutic approach, it is critical to understand the underlying sex and sex hormone-mediated
differences in MCT/SMCT transport kinetics. Administration of MCT inhibitors, such as Llactate, results in an increase in GHB renal and total clearance in rats (Felmlee et al., 2013;
Morse & Morris, 2013a; Roiko et al., 2013a; Q. Wang et al., 2008). Similarly, SMCT1 is
involved in renal reabsorption of lactate and pyruvate, which also function as SMCT1 inhibitors
(Cui & Morris, 2009; Ganapathy et al., 2008; Gopal et al., 2007). The observed decreases in
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GHB renal clearance with lactate administration are likely due to inhibition of MCTs and
SMCTs. After luteolin treatment, the renal and total clearances of GHB are significantly
increased because of inhibition of the MCT1-mediated renal reabsorption of GHB (Q. Wang &
Morris, 2007). As well, the immunosuppressive compounds AR-C117977 and AR-C122982 are
potent MCT1 inhibitors (Pahlman et al., 2013), and co-administration with GHB lead to
increased GHB renal and total clearance (Vijay et al., 2015). However, GHB renal clearance
remains less than filtration clearance suggesting that other monocarboxylate transporter
contribute to active renal reabsorption of GHB. Due to the contribution of multiple
monocarboxylate transporters to active renal reabsorption of GHB, future studies evaluating sex
hormone dependent transporter expression should evaluate these multiple pathways.
MCTs are located on the basolateral membrane of renal proximal tubules (Morris &
Felmlee, 2008), while SMCTs are located on the apical membrane of renal proximal tubules
(Yanase, Takebe, Nio-Kobayashi, Takahashi-Iwanaga, & Iwanaga, 2008). MCTs and SMCTs
function to remove GHB from the tubular fluid and return it to systemic circulation (Morris et
al., 2005). Varied expression of MCTs and SMCTs in the kidney can alter renal reabsorption of
GHB due to alteration in the maximum capacity for renal reabsorption (Felmlee et al., 2013). In
the case of proestrus females, the total amount excreted in the urine increased likely due to
decreased active renal reabsorption of GHB suggesting the proestrus females have decreased
renal expression of MCTs/SMCTs. Similarly, renal clearance will be lower if MCT/SMCT
expression in the kidney is greater due to an increase capacity for active renal reabsorption of
GHB which leads to a decrease in overall GHB elimination (Morse & Morris, 2013a; Vijay et
al., 2015). This is consistent with the observed results in males, diestrus females and OVX
females. Studies are currently underway in our laboratory to quantify renal MCT/SMCT
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expression in males, over the estrus cycle in females and in the absence of male and female sex
hormones.
MCTs expression has been demonstrated to be regulated by sex hormones in Sertoli cells,
skeletal muscle and brain (Enoki et al., 2006; Manente et al., 2015; Rato et al., 2012); however,
there is minimal data in tissues involved in drug distribution. In Sertoli cells, the MCT 4 mRNA
level significantly decreased in 17β-oestradiol and dihydrotestosterone treatment groups (Rato et
al., 2012). Administration of testosterone increased MCT1 and MCT4 protein expression in rat
skeletal muscle (Enoki et al., 2006). Oestrogen-related receptor alpha (ERRα) expression can
modulate the expression of MCT1 in mice (Aveseh et al., 2015), and the induction of estrogen
receptor β (ERβ) expression result in the expression of MCT4 in mesothelioma cells of mice
(Aveseh et al., 2015). The absence of female sex hormones after ovariectomy (OVX) induced a
decrease of MCT2 expression in brain of mice (Manente et al., 2015). Taken together these
results suggest that sex hormones regulate monocarboxylate transporters; however, the observed
alterations in expression differ between tissues. Previous studies in our laboratory have shown
that MCT1 and MCT4 are regulated in a sex and sex hormone-dependent manner in the liver
(Cao et al., 2017). MCT1 and MCT4 membrane expression is lower in proestrus females, as
compared to males and OVX females (Cao et al., 2017). These expression changes are consistent
with our predicted changes in renal MCT expression based on our observed renal clearance
changes (renal clearance of proestrus females is the highest compared the other groups).
Preliminary data from our laboratory indicates that renal MCT1 membrane expression is lower in
proestrus and metestrus females as compared to males and OVX females (J. Cao and MA
Felmlee, unpublished data), which is consistent with our observed renal clearance data.
However, renal SMCT expression data in females over the estrus cycle is not currently available
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in the literature and needs to be evaluated to predict changes in renal clearance. In addition, our
preliminary data in castrated male rats demonstrated significantly higher kidney MCT1
membrane expression as compared to all females, which may lead to extensive reabsorption of
GHB and a significantly lower GHB renal clearance. Such changes may lead to significantly
increased systemic GHB plasma concentration corresponding to an increased risk of fatality, and
accordingly castrated males should be included in future toxicokinetic studies.
There are limited studies on SMCT1 expression in response to exogenous sex
hormones. Progesterone decreased protein expression of SMCT1 (Takiue, Hosoyamada, Kimura,
& Saito, 2011). However, there is lack of data on renal SMCT1 and SMCT2 expression in
females over the estrus cycle and in the absence of sex hormones, which should be included to
predict the renal clearance in combination with MCT1 renal expression. Further, MCT and
SMCT expression has not been evaluated in response to treatment with exogenous sex hormones.
The contribution of individual sex hormones to the regulation of renal MCT/SMCT expression is
not currently known. With respect to metabolic clearance, there is a lack of metabolic enzyme
expression in response to sex hormones; however, there appears to be no sex differences in
metabolic clearance.
In summary, we have demonstrated that GHB toxicokinetics and renal clearance differs
between sexes, over the estrus cycle in females, and in the absence of female sex hormones
following intravenous administration. GHB renal clearance varied significantly over the estrus
cycles with diestrus and OVX females having significantly lower GHB renal clearance. As a
moderate GHB dose was used in this study, future studies should evaluate higher GHB doses to
determine differences between the sexes in GHB overdose and fatality potential. In addition,
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hormone replacement studies should be conducted to confirm the role of individual sex
hormones on the toxicokinetics of GHB.
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